Browse hierarchy: [General Hospital (HO)](/submissions/HO) → [Subpart F — Therapeutic Devices](/submissions/HO/subpart-f%E2%80%94therapeutic-devices) → [21 CFR 868.5480](/submissions/HO/subpart-f%E2%80%94therapeutic-devices/868.5480) → QFB — Isocapnic Ventilation Device

# QFB · Isocapnic Ventilation Device

_General Hospital · 21 CFR 868.5480 · Class 2_

**Canonical URL:** https://fda.innolitics.com/submissions/HO/subpart-f%E2%80%94therapeutic-devices/QFB

## Overview

- **Product Code:** QFB
- **Device Name:** Isocapnic Ventilation Device
- **Regulation:** [21 CFR 868.5480](/submissions/HO/subpart-f%E2%80%94therapeutic-devices/868.5480)
- **Device Class:** 2
- **Review Panel:** [General Hospital](/submissions/HO)

## Identification

An isocapnic ventilation device is a prescription device used to administer a blend of carbon dioxide and oxygen gases to a patient to induce hyperventilation. This device may be labeled for use with breathing circuits made of reservoir bags (§ 868.5320), oxygen cannulas (§ 868.5340), masks (§ 868.5550), valves (§ 868.5870), resuscitation bags (§ 868.5915), and/or tubing (§ 868.5925).

## Classification Rationale

Class II (special controls). The special controls for this device are:

## Special Controls

In combination with the general controls of the FD&C Act. the isocapnic ventilation device is subject to the following special controls:

*Classification.* Class II (special controls). The special controls for this device are:(1) Nonclinical performance testing data must demonstrate that the device performs as intended under anticipated conditions of use, including the following performance characteristics:
(i) Gas concentration accuracy testing for the range of intended concentrations;
(ii) Airway pressure delivery accuracy testing;
(iii) Supplemental O
2 flowrate accuracy testing;(iv) Alarm testing; and
(v) Use life testing.
(2) The patient-contacting components of the device must be demonstrated to be biocompatible.
(3) Labeling must include the following:
(i) Instructions for use;
(ii) A precaution that monitoring of capnography is necessary during treatment with non-spontaneously breathing patients; and
(iii) Use life specification.

## Recent Cleared Devices (1 of 1)

| Record | Device Name | Applicant | Decision Date | Decision |
| --- | --- | --- | --- | --- |
| [DEN170044](https://fda.innolitics.com/submissions/HO/subpart-f%E2%80%94therapeutic-devices/QFB/DEN170044.md) | ClearMate | Thornhill Research, Inc. | Mar 14, 2019 | DENG |

## Top Applicants

- Thornhill Research, Inc. — 1 clearance

---

**Source:** [https://fda.innolitics.com/submissions/HO/subpart-f%E2%80%94therapeutic-devices/QFB](https://fda.innolitics.com/submissions/HO/subpart-f%E2%80%94therapeutic-devices/QFB)

**Published by [Innolitics](https://innolitics.com)** — a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices. If you're preparing [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/), [get in touch](https://innolitics.com/contact).

**Cite:** Innolitics at https://innolitics.com